Brockmann Bobbi Jo 4

What Happened
Bobbi Jo Brockmann, VP of Sales & Marketing and a director of ImmuCell Corp (ICCC), received an award of 5,000 derivative securities (options) on April 16, 2025. The grant is reported at $0.00 cash paid in the Form 4; the filing classifies the transaction as an award/grant (code A). This is a compensation grant to a board member, not an open‑market purchase or sale.

Key Details

• Transaction date: 2025-04-16 (reported on Form 4 filed 2026-04-14; late filing).
• Transaction type/code: Award/Grant (A) of derivative securities (options).
• Quantity: 5,000 derivative shares; reported price: $0.00; reported value: $0.
• Shares/derivative owned after transaction: not specified in this filing.
• Remark on grant: “The options were granted by the Issuer to compensate directors for services on the Issuer's board of directors.”
• Filing timeliness: Late (reporting period 2025-04-16; Form 4 filed 2026-04-14). Late filings reduce transparency and may require explanation or lead to SEC follow-up.

Context
This was a standard director compensation award of options (a derivative grant). The filing does not disclose vesting or exercise terms, nor whether options are immediately exercisable; no shares were sold or purchased in this transaction. The economic value to the insider depends on future vesting and the company’s stock performance; the Form 4 itself reports no cash exchanged at grant.